0000950170-23-041889.txt : 20230811 0000950170-23-041889.hdr.sgml : 20230811 20230811163048 ACCESSION NUMBER: 0000950170-23-041889 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230811 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230811 DATE AS OF CHANGE: 20230811 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REVELATION BIOSCIENCES, INC. CENTRAL INDEX KEY: 0001810560 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 843898466 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39603 FILM NUMBER: 231164579 BUSINESS ADDRESS: STREET 1: 4660 LAJOLLA VILLAGE DRIVE STREET 2: SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92122 BUSINESS PHONE: 650-800-3717 MAIL ADDRESS: STREET 1: 4660 LAJOLLA VILLAGE DRIVE STREET 2: SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92122 FORMER COMPANY: FORMER CONFORMED NAME: Petra Acquisition Inc. DATE OF NAME CHANGE: 20200423 8-K 1 revb-20230811.htm 8-K 8-K
false00018105600001810560revb:RedeemableWarrantsEachExercisableForOneByThirtyFifthShareOfCommonStockAtExercisePriceOf40250PerShareMember2023-08-112023-08-110001810560revb:CommonStockParValue0001PerShareMember2023-08-112023-08-1100018105602023-08-112023-08-11

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 11, 2023

 

 

REVELATION BIOSCIENCES, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39603

84-3898466

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

4660 La Jolla Village Drive

Suite 100

 

San Diego, California

 

92122

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (650) 800-3717

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common stock, par value $0.001 per share

 

REVB

 

The Nasdaq Stock Market LLC

Redeemable warrants, each exercisable for a 1/35th share of common stock at an exercise price of $402.50 per share

 

REVBW

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 2.02 Results of Operations and Financial Condition.

On August 11, 2023, Revelation Biosciences, Inc. issued a press release announcing its financial results for the three and six months ended June 30, 2023. A copy of the press release is furnished as Exhibit 99.1.

The information in Item 2.02 and in Exhibit 99.1 will not be treated as “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or into another filing under the Exchange Act, unless that filing expressly incorporates this information by reference.


Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

 

 

 

Exhibit No.

 

Description

99.1

 

Press release, dated August 11, 2023




 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

REVELATION BIOSCIENCES, INC.

 

 

 

 

Date:

August 11, 2023

By:

/s/ Chester S. Zygmont, III

 

 

 

Chester S. Zygmont, III
Chief Financial Officer
(principal financial and accounting officer)
 

 

 EX-99.1 2 revb-ex99_1.htm EX-99.1 EX-99.1

Exhibit 99.1

 

img220778470_0.jpg 

Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2023

San Diego, CA – August 11, 2023 – Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today reported its three and six months ended June 30, 2023 financial results.

Results of Operations

As of June 30, 2023, Revelation had $15.7 million in cash and cash equivalents, compared to $5.3 million as of December 31, 2022. The increase in cash and cash equivalents was primarily due to net cash received from financing activities, offset primarily by cash used for operating activities. Based on current operating plans and projections, Revelation believes that its current cash and cash equivalents are sufficient to fund operations through June of 2024.

Revelation’s net cash used for operating activities for the six months ended June 30, 2023 was $3.6 million compared to net cash used for operating activities of $8.5 million for the same period in 2022. Revelation’s net loss for the three months ended June 30, 2023 was $1.4 million, or $0.25 basic and diluted net loss per share, compared to a net loss of $1.8 million, or $4.16 basic and diluted net loss per share for the same period in 2022. Revelation’s net income for the six months ended June 30, 2023 was $4.7 million, or $1.61 basic net earnings per share and $1.53 diluted net earnings per share, compared to a net loss of $8.5 million, or $19.71 basic and diluted net loss per share for the same period in 2022.

 

Net income for the six months ended June 30, 2023 was primarily due to the change in fair value of the warrant liability creating a $8.2 million gain. The changes in net cash used for operating activities and the decrease in net loss in 2023 as compared to 2022 were primarily due to decreased clinical study expenses associated with our Phase 2b viral challenge clinical study (REVTx-99a) and our Phase 1b allergen challenge study (REVTx-99b), legal fees, professional consulting service fees and public company directors and officers insurance policy.

 

About Revelation Biosciences Inc.

Revelation Biosciences, Inc. is a life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has multiple product candidates in development that are based on the well-established biology of phosphorylated hexaacyl disaccharide (PHAD) and its effect on the innate immune system. REVTx‑300 is being developed as a potential therapy for the treatment of acute and chronic organ disease including CKD, AKI and myocarditis. REVTx‑100 is being developed as a prevention and treatment of infection. REVTx‑200 is being developed as an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx‑99b is being developed as a treatment for food allergies.

For more information on Revelation, please visit www.RevBiosciences.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions. We caution investors that forward-looking statements are based on management’s expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation’s product candidates; the clinical utility of an increase in intranasal cytokine levels as a biomarker of viral infections; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the potential impact that COVID-19 may have on Revelation’s suppliers, vendors, regulatory agencies, employees and the global economy as a whole; the ability of Revelation to maintain the listing of its securities on NASDAQ; investor sentiment relating to SPAC related going public transactions; the expected duration over which Revelation’s balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.

 

 

REVELATION BIOSCIENCES, INC.

Condensed Consolidated Statements of Operations

(Unaudited)

 

 

 

Three Months Ended
June 30,

 

 

Six Months Ended
June 30,

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

909,278

 

 

$

975,583

 

 

$

1,434,551

 

 

$

4,655,863

 

General and administrative

 

 

1,023,752

 

 

 

884,837

 

 

 

2,118,326

 

 

 

3,790,857

 

Total operating expenses

 

 

1,933,030

 

 

 

1,860,420

 

 

 

3,552,877

 

 

 

8,446,720

 

Loss from operations

 

 

(1,933,030

)

 

 

(1,860,420

)

 

 

(3,552,877

)

 

 

(8,446,720

)

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

Change in fair value of warrant liability

 

 

423,239

 

 

 

—

 

 

 

8,168,174

 

 

 

—

 

Other income (expense)

 

 

61,621

 

 

 

25,734

 

 

 

95,728

 

 

 

(4,507

)

Total other income (expense), net

 

 

484,860

 

 

 

25,734

 

 

 

8,263,902

 

 

 

(4,507

)

Net (loss) income

 

$

(1,448,170

)

 

$

(1,834,686

)

 

$

4,711,025

 

 

$

(8,451,227

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Net (loss) earnings per share, basic

 

$

(0.25

)

 

$

(4.16

)

 

$

1.61

 

 

$

(19.71

)

Weighted-average shares used to compute net (loss) earnings per share, basic

 

 

5,812,278

 

 

 

441,351

 

 

 

2,922,195

 

 

 

428,837

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net (loss) earnings per share, diluted

 

$

(0.25

)

 

$

(4.16

)

 

$

1.53

 

 

$

(19.71

)

Weighted-average shares used to compute net (loss) earnings per share, diluted

 

 

5,812,278

 

 

 

441,351

 

 

 

3,072,695

 

 

 

428,837

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

REVELATION BIOSCIENCES, INC.

Condensed Consolidated Balance Sheets

(Unaudited)

 

 

 

June 30,
2023

 

 

December 31,
2022

 

ASSETS

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

15,711,218

 

 

$

5,252,979

 

Deferred offering costs

 

 

—

 

 

 

87,171

 

Prepaid expenses and other current assets

 

 

250,012

 

 

 

73,132

 

Total current assets

 

 

15,961,230

 

 

 

5,413,282

 

Property and equipment, net

 

 

77,608

 

 

 

90,133

 

Total assets

 

$

16,038,838

 

 

$

5,503,415

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

913,866

 

 

$

554,205

 

Accrued expenses

 

 

496,870

 

 

 

985,497

 

Deferred underwriting commissions

 

 

2,911,260

 

 

 

2,911,260

 

Warrant liability

 

 

302,039

 

 

 

—

 

Total current liabilities

 

 

4,624,035

 

 

 

4,450,962

 

Total liabilities

 

 

4,624,035

 

 

 

4,450,962

 

Stockholders’ equity:

 

 

 

 

 

 

Series A Preferred Stock, $0.001 par value; zero and one shares authorized, issued and outstanding at June 30, 2023 and December 31, 2022, respectively; liquidation preference of $0 and $5,000 at June 30, 2023 and December 31, 2022, respectively

 

 

—

 

 

 

—

 

Common Stock, $0.001 par value; 500,000,000 and 11,000,000 shares authorized and 6,297,303 and 682,882 issued and outstanding at June 30, 2023 and December 31, 2022, respectively

 

 

6,297

 

 

 

683

 

Additional paid-in-capital

 

 

32,044,329

 

 

 

26,398,618

 

Accumulated deficit

 

 

(20,635,823

)

 

 

(25,346,848

)

Total stockholders’ equity

 

 

11,414,803

 

 

 

1,052,453

 

Total liabilities and stockholders’ equity

 

$

16,038,838

 

 

$

5,503,415

 

 

Company Contacts

 

Sandra Vedrick

Vice President, Investor Relations & Human Resources

Revelation Biosciences Inc.

Email: svedrick@revbiosciences.com

 

and

 

Chester Zygmont, III

Chief Financial Officer

Revelation Biosciences Inc.

Email: czygmont@revbiosciences.com

GRAPHIC 3 img220778470_0.jpg GRAPHIC begin 644 img220778470_0.jpg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end EX-101.PRE 4 revb-20230811_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 5 revb-20230811.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 6 revb-20230811_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 7 revb-20230811_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity Ex Transition Period Securities Act File Number Entity Incorporation, State or Country Code Entity Information, Former Legal or Registered Name Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications Document Information [Table] Document Information [Line Items] Common stock, par value 0.001 per share. Common Stock, Par Value $0.001 Per Share [Member] Class of Stock [Axis] Class of Stock [Domain] Redeemable warrants, each exercisable for one by thirty fifth share of common stock at exercise price of 402.50 per share. Redeemable Warrants, Each Exercisable For One By Thirty Fifth Share Of Common Stock At Exercise Price Of $402.50 Per Share [Member] XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document And Entity Information
Aug. 11, 2023
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 11, 2023
Entity Registrant Name REVELATION BIOSCIENCES, INC.
Entity Central Index Key 0001810560
Entity Emerging Growth Company true
Securities Act File Number 001-39603
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 84-3898466
Entity Address, Address Line One 4660 La Jolla Village Drive
Entity Address, Address Line Two Suite 100
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92122
City Area Code (650)
Local Phone Number 800-3717
Entity Information, Former Legal or Registered Name Not Applicable
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Common Stock, Par Value $0.001 Per Share [Member]  
Document Information [Line Items]  
Title of 12(b) Security Common stock, par value $0.001 per share
Trading Symbol REVB
Security Exchange Name NASDAQ
Redeemable Warrants, Each Exercisable For One By Thirty Fifth Share Of Common Stock At Exercise Price Of $402.50 Per Share [Member]  
Document Information [Line Items]  
Title of 12(b) Security Redeemable warrants, each exercisable for a 1/35th share of common stock at an exercise price of $402.50 per share
Trading Symbol REVBW
Security Exchange Name NASDAQ
XML 9 revb-20230811_htm.xml IDEA: XBRL DOCUMENT 0001810560 revb:RedeemableWarrantsEachExercisableForOneByThirtyFifthShareOfCommonStockAtExercisePriceOf40250PerShareMember 2023-08-11 2023-08-11 0001810560 revb:CommonStockParValue0001PerShareMember 2023-08-11 2023-08-11 0001810560 2023-08-11 2023-08-11 false 0001810560 8-K 2023-08-11 REVELATION BIOSCIENCES, INC. DE 001-39603 84-3898466 4660 La Jolla Village Drive Suite 100 San Diego CA 92122 (650) 800-3717 Not Applicable false false false false Common stock, par value $0.001 per share REVB NASDAQ Redeemable warrants, each exercisable for a 1/35th share of common stock at an exercise price of $402.50 per share REVBW NASDAQ true false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 3 25 1 false 2 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://revbiosciences.com/20230811/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports revb-20230811.htm revb-20230811.xsd revb-20230811_def.xml revb-20230811_lab.xml revb-20230811_pre.xml revb-ex99_1.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "revb-20230811.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 28 }, "contextCount": 3, "dts": { "definitionLink": { "local": [ "revb-20230811_def.xml" ] }, "inline": { "local": [ "revb-20230811.htm" ] }, "labelLink": { "local": [ "revb-20230811_lab.xml" ] }, "presentationLink": { "local": [ "revb-20230811_pre.xml" ] }, "schema": { "local": [ "revb-20230811.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 32, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 25, "memberCustom": 2, "memberStandard": 0, "nsprefix": "revb", "nsuri": "http://revbiosciences.com/20230811", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "revb-20230811.htm", "contextRef": "C_4898d3f9-c33a-492e-9455-83396adbfcb4", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://revbiosciences.com/20230811/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "revb-20230811.htm", "contextRef": "C_4898d3f9-c33a-492e-9455-83396adbfcb4", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://revbiosciences.com/20230811/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://revbiosciences.com/20230811/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://revbiosciences.com/20230811/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://revbiosciences.com/20230811/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://revbiosciences.com/20230811/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://revbiosciences.com/20230811/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://revbiosciences.com/20230811/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://revbiosciences.com/20230811/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://revbiosciences.com/20230811/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://revbiosciences.com/20230811/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://revbiosciences.com/20230811/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://revbiosciences.com/20230811/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://revbiosciences.com/20230811/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://revbiosciences.com/20230811/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://revbiosciences.com/20230811/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://revbiosciences.com/20230811/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://revbiosciences.com/20230811/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://revbiosciences.com/20230811/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://revbiosciences.com/20230811/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://revbiosciences.com/20230811/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://revbiosciences.com/20230811/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://revbiosciences.com/20230811/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://revbiosciences.com/20230811/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://revbiosciences.com/20230811/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://revbiosciences.com/20230811/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://revbiosciences.com/20230811/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://revbiosciences.com/20230811/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "revb_CommonStockParValue0001PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock, par value 0.001 per share.", "label": "Common Stock, Par Value $0.001 Per Share [Member]" } } }, "localname": "CommonStockParValue0001PerShareMember", "nsuri": "http://revbiosciences.com/20230811", "presentation": [ "http://revbiosciences.com/20230811/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "revb_RedeemableWarrantsEachExercisableForOneByThirtyFifthShareOfCommonStockAtExercisePriceOf40250PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redeemable warrants, each exercisable for one by thirty fifth share of common stock at exercise price of 402.50 per share.", "label": "Redeemable Warrants, Each Exercisable For One By Thirty Fifth Share Of Common Stock At Exercise Price Of $402.50 Per Share [Member]" } } }, "localname": "RedeemableWarrantsEachExercisableForOneByThirtyFifthShareOfCommonStockAtExercisePriceOf40250PerShareMember", "nsuri": "http://revbiosciences.com/20230811", "presentation": [ "http://revbiosciences.com/20230811/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://revbiosciences.com/20230811/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://revbiosciences.com/20230811/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0000950170-23-041889-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-041889-xbrl.zip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end